Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Procaps Group ( (PROC) ).
Procaps Group, a notable player in the healthcare and pharmaceutical industry, announced that it received an additional delinquency letter from Nasdaq due to late filing of its interim financial statements for the period ending June 30, 2024. This notice adds to the existing delay in the filing of their Form 20-F for the fiscal year 2023. The Nasdaq Hearings Panel will consider this delinquency while deliberating on the company’s request for continued listing. Procaps is preparing to address this issue and present a compliance plan at an upcoming hearing.
More about Procaps Group
Procaps Group, S.A. is a leading developer of pharmaceutical and nutraceutical solutions, providing medicines and hospital supplies across more than 50 countries on five continents. With a direct presence in 13 countries in the Americas and nearly 5,000 employees, Procaps operates under a sustainable model, offering a range of over-the-counter (OTC) pharmaceutical products, prescription drugs (Rx), nutritional supplements, and high-potency clinical solutions.
YTD Price Performance: 0.0%
Average Trading Volume: 102,509
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $262.9M
Find detailed analytics on PROC stock on TipRanks’ Stock Analysis page.
